<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>KLOR-CON/EF- potassium bicarbonate tablet, effervescent </strong><br>Sandoz Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>KLOR-CON<span class="Sup">®</span>/EF</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">Potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Effervescent<br>Tablets for Oral Solution, USP<br>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>Description</h1>
<p class="First">Orange-flavored KLOR-CON<span class="Sup">®</span>/EF Potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Effervescent Tablets for Oral Solution, USP are an oral potassium supplement offered as effervescent tablets in individual packets for dissolution in water. Each tablet contains potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> 2.5 g and citric acid 2 .1g which in solution provides 25 mEq (978 mg) potassium as <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and citrate. Also contains: FD&amp;C Yellow No. 6, FD&amp;C Yellow No. 6 Lake, microcrystalline cellulose, mineral oil, orange flavor, saccharin and talc. KLOR-CON<span class="Sup">®</span>/EF tablets are sugar-free.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes, including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function.</p>
<p>The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.</p>
<p>Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.</p>
<p>Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primary or secondary hyperaldosteronism, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, especially if associated with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>. Potassium depletion may produce <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram and, in advanced cases, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> and/or impaired ability to concentrate urine.</p>
<p>If potassium depletion associated with <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span> cannot be managed by correcting the fundamental cause of the deficiency (e.g., patients require long-term diuretic therapy), supplemental potassium in the form of high potassium food or potassium salts may be able to restore normal potassium levels.</p>
<p>In rare circumstances (e.g., patients with <span class="product-label-link" type="condition" conceptid="4070448" conceptname="Renal tubular acidosis">renal tubular acidosis</span>), potassium depletion may be associated with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4253927" conceptname="Hyperchloremia">hyperchloremia</span>. In such patients, potassium replacement should be accomplished with potassium salts such as potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, potassium citrate, potassium acetate or potassium gluconate.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>Indications and Usage</h1>
<dl>
<dt>1.</dt>
<dd> For the treatment of patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, with or without <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>; in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span>; and in patients with hypokalemic <span class="product-label-link" type="condition" conceptid="73184" conceptname="Familial periodic paralysis">familial periodic paralysis</span>. If <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is the   result of diuretic therapy, consideration should be given to the use of a   lower dose of diuretic, which may be sufficient without leading to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</dd>
<dt>2.</dt>
<dd> For the prevention of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in patients who would be at particular risk if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> were to develop (e.g., digitalized patients or patients with significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>).</dd>
</dl>
<p class="First">The use of potassium salts in patients receiving diuretics for uncomplicated <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-5"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Potassium supplements are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> since a further increase in serum potassium concentration in such patients can produce <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> may complicate any of the following conditions: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, systemic <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> such as <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic acidosis</span>, acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, extensive tissue breakdown as in severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride) (see <span class="Bold"><a href="#Overdosage">Overdosage</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>Warnings</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">(see <span class="Bold"><a href="#Overdosage">Overdosage</a></span>) 									</p>
<p>In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Interaction with Potassium-Sparing Diuretics</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride), since the simultaneous administration of these agents can produce severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Interaction with Angiotensin Converting Enzyme Inhibitors</h2>
<p class="First">Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> in patients with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> should be treated with an alkalinizing potassium salt such as potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, potassium citrate, potassium acetate or potassium gluconate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>Precautions</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The diagnosis of potassium depletion is ordinarily made by demonstrating <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should be aware that acute <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> <span class="Italics">per se </span>can produce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in the absence of a deficit in total body potassium while <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acute acidosis</span> <span class="Italics">per se </span>can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram and the clinical status of the patient.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Remind the patient to take this medicine following the frequency and amount prescribed. This is especially important if the patient is also taking diuretics and/or digitalis preparations.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">When blood is drawn for analysis of plasma potassium, artifactual elevations can occur after improper venipuncture technique or as a result of <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> of the sample.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Potassium-sparing diuretics, angiotensin converting enzyme inhibitors (see <span class="Bold"><a href="#Warnings">Warnings</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Animal reproduction studies have not been conducted with potassium salts. It is not known if potassium salts cause fetal harm when administered to a pregnant woman or affect reproductive capacity. Potassium supplements should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from oral potassium supplements, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First">One of the most severe adverse effects is <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <span class="Bold"><a href="#Contraindications">Contraindications</a>, <a href="#Warnings">Warnings</a></span> and <span class="Bold"><a href="#Warnings"></a><a href="#Overdosage">Overdosage</a></span>).</p>
<p>The most common adverse reactions to oral potassium salts are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the dose.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Overdosage"></a><a name="section-9"></a><p></p>
<h1>Overdosage</h1>
<p class="First">The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can result (see <span class="Bold"><a href="#Contraindications">Contraindications</a></span> and <span class="Bold"><a href="#Warnings">Warnings</a></span>). It is important to recognize that <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of S-T segment and prolongation of the QT interval). Late manifestations include muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (9-12 mEq/L).</p>
<p>Treatment measures for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include the following: 1) elimination of foods and medications containing potassium and elimination of potassium-sparing diuretics; 2) intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL; 3) correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, if present, with intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>; 4) use of exchange resins, hemodialysis or peritoneal dialysis.</p>
<p>In treating <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> usually requires the loss of 200 mEq or more of potassium from the total body store.</p>
<p>Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is typically 25 mEq per day. Doses of 50 to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 25 mEq per day is given such that no more than 25 mEq is given in a single dose.</p>
<p>The usual adult dose is 25 to 100 mEq of potassium per day (one KLOR-CON<span class="Sup">®</span>/EF tablet 1 to 4 times daily after meals).</p>
<p>Each KLOR-CON<span class="Sup">®</span>/EF tablet should be dissolved in at least 4 ounces of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or ice water. These preparations, like other potassium supplements, must be properly diluted to avoid the possibility of <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>How Supplied</h1>
<p class="First">KLOR-CON<span class="Sup">®</span>/EF Potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Effervescent Tablets for Oral Solution, USP are supplied in cartons of 30 individually wrapped tablets (NDC 66758-140-34) and cartons of 100 individually wrapped tablets (NDC 66758-140-81).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store at controlled room temperature, 15-30°C (59-86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured for<br><span class="Bold">Sandoz Inc. </span>Princeton, NJ 08540</p>
<p>by Nomax, Inc., St. Louis, MO 63123</p>
<p>Klor-Con is a registered trademark of Upsher-Smith Laboratories, Inc.</p>
<p>Revised 0414</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 978 mg Tablet Pouch Carton</h1>
<p class="First"><span class="Bold">NDC</span> 66758-140-34</p>
<p><span class="Bold">Klor-Con<span class="Sup">®</span>/EF</span></p>
<p><span class="Bold">Potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span><br>Effervescent Tablets<br>for Oral Solution, USP</span></p>
<p><span class="Bold">Orange-Flavored</span></p>
<p><span class="Bold">25 mEq (978 mg)<br>Potassium per Tablet</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 Tablets</span></p>
<p><span class="Bold">SANDOZ<br></span>a Novartis company</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 978 mg Tablet Pouch Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=731d4e0d-e73b-41ef-a39f-c356d999734d&amp;name=klor-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KLOR-CON/EF 		
					</strong><br><span class="contentTableReg">potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> tablet, effervescent</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66758-140</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span></strong> (potassium cation) </td>
<td class="formItem">potassium cation</td>
<td class="formItem">978 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C yellow no. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>light mineral oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>saccharin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">25mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66758-140-34</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66758-140-94</td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66758-140-81</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66758-140-94</td>
<td class="formItem">1  in 1 POUCH; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">09/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sandoz Inc.
							(005387188)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Upsher-Smith Laboratories, Inc. (047251004)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nomax Inc.</td>
<td class="formItem"></td>
<td class="formItem">103220273</td>
<td class="formItem">MANUFACTURE(66758-140), ANALYSIS(66758-140), LABEL(66758-140), PACK(66758-140)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bf7893d6-6ead-4c63-b71d-2862fa8a6d52</div>
<div>Set id: 731d4e0d-e73b-41ef-a39f-c356d999734d</div>
<div>Version: 1</div>
<div>Effective Time: 20140812</div>
</div>
</div> <div class="DistributorName">Sandoz Inc.</div></p>
</body></html>
